{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:34:17Z","timestamp":1775054057248,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,29]],"date-time":"2019-12-29T00:00:00Z","timestamp":1577577600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009431","name":"Baxalta","doi-asserted-by":"publisher","award":["Study sponsor"],"award-info":[{"award-number":["Study sponsor"]}],"id":[{"id":"10.13039\/100009431","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shire","award":["Funded medical writing support"],"award-info":[{"award-number":["Funded medical writing support"]}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["Funded medical writing support and publication charges"],"award-info":[{"award-number":["Funded medical writing support and publication charges"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>L-asparaginase is a key component of treatment for patients with acute lymphoblastic leukaemia (ALL) in the UK. Commonly used forms of asparaginase are native <jats:italic>E. coli<\/jats:italic>-derived asparaginase (native asparaginase) and pegaspargase in first-line combination therapy, and native <jats:italic>Erwinia chrysanthemi<\/jats:italic>-derived asparaginase (Erwinia asparaginase) as second-line treatment. The objective of this study was to evaluate the cost-effectiveness of pegaspargase versus native asparaginase in first-line combination therapy for patients with newly diagnosed ALL. A combined decision tree and health-state transition Markov cost-effectiveness model was developed to assess the relative costs and health outcomes of pegaspargase versus native asparaginase in the UK setting.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In base case analyses, first-line pegaspargase (followed by Erwinia asparaginase in cases of hypersensitivity) dominated first-line native asparaginase followed by Erwinia asparaginase; i.e. resulted in lower costs and more quality-adjusted life year gain. The favourable hypersensitivity rates and administration profile of pegaspargase led to lifetime cost savings of \u00a34741 versus native asparaginase. Pegaspargase remained cost-effective versus all treatment strategies in all scenario analyses, including use of the 2500\u2009IU\/m<jats:sup>2<\/jats:sup> dose, recommended for patients \u226421\u2009years of age.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Pegaspargase, as part of multi-drug chemotherapy, is a cost-effective option for the treatment of newly diagnosed ALL. Based on this study, The National Institute for Health and Care Excellence Technology Appraisal Committee concluded that it could recommend pegaspargase as a cost-effective use of National Health Service resources in England &amp; Wales for treating ALL in children, young people and adults with untreated, newly diagnosed disease.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>UKALL 2011, EudraCT number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020924-22\/GB\">2010-020924-22<\/jats:ext-link>; UKALL 2003, EudraCT number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN07355119\">2007-004013-34<\/jats:ext-link>; UKALL14, EudraCT number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-012717-22\/GB\">2009-012717-22<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13561-019-0257-3","type":"journal-article","created":{"date-parts":[[2019,12,29]],"date-time":"2019-12-29T10:02:28Z","timestamp":1577613748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis"],"prefix":"10.1186","volume":"9","author":[{"given":"Xingdi","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley P.","family":"Wildman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subham","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy L.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Rowntree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-9649","authenticated-orcid":false,"given":"Vaskar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,29]]},"reference":[{"key":"257_CR1","unstructured":"Cancer Research UK. Acute lymphoblastic leukaemia (ALL) incidence statistics. In:  Cancer statistics: Cancer Research UK; 2016. http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-all\/incidence#heading-Zero. Accessed 10 Oct 2019."},{"key":"257_CR2","unstructured":"Cancer Research UK. Acute lymphoblastic leukaemia (ALL) incidence by age. In: Cancer Statistics. Cancer Research UK. 2016. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-all\/incidence#heading-One. Accessed 10 Oct 2019."},{"key":"257_CR3","unstructured":"Cancer Research UK & UCL Cancer Trials Centre. UKALL14 A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia. 2015 10.12.2015. Report No.: EUDRACT no: 2009\u2013012717-22 Contract No.: Version 7.0, 09.09.2015 \u2014 corrected version 10.12.2015."},{"key":"257_CR4","unstructured":"Cancer Research UK Clinical Trials Unit. UKALL 2011 Trial (United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011). 2013 01\/10\/2013. Report No.: Eudract No: 2010\u2013020924-22 Contract No.: Version 3.0."},{"key":"257_CR5","volume-title":"UK national randomised trial for children and young adults with acute lymphoblastic leukaemia (UKALL 2003)","author":"Medical Research Council Working Party on Leukaemia in Children","year":"2009","unstructured":"Medical Research Council Working Party on Leukaemia in Children. UK national randomised trial for children and young adults with acute lymphoblastic leukaemia (UKALL 2003). 2009."},{"key":"257_CR6","unstructured":"ClinicalTrials.gov. Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003. In: ClinicalTrialsgov. NIH US National Library of Medicine. 2005. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00222612. Accessed 11 Oct 2019."},{"key":"257_CR7","unstructured":"ClinicalTrials.gov. Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia. In: ClinicalTrialsgov. NIH US National Library of Medicine. 2010. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01085617. Accessed 11 Oct 2019."},{"key":"257_CR8","unstructured":"University of Birmingham. United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011. In: EU Clinical Trials Register European Medicines Agency. 2011. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020924-22\/GB. Accessed 14 Oct 2019."},{"issue":"4","key":"257_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"VI Avramis","year":"2005","unstructured":"Avramis VI, Panosyan EH. Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367\u201393.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"257_CR10","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood. 2002;99(6):1986\u201394.","journal-title":"Blood."},{"key":"257_CR11","doi-asserted-by":"crossref","unstructured":"Medawar CV, Mosegui GBG, Vianna CMM, Costa T. PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review. Hematol Transfus Cell Ther. 2019.","DOI":"10.1016\/j.htct.2019.01.013"},{"issue":"12","key":"257_CR12","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1080\/10428194.2019.1608530","volume":"60","author":"Bernard L. Marini","year":"2019","unstructured":"Marini BL, Brown J, Benitez L, Walling E, Hutchinson RJ, Mody R, et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019:60(12):2854-2868.","journal-title":"Leukemia & Lymphoma"},{"key":"257_CR13","unstructured":"Les Laboratoires Servier. ONCASPAR\u00ae summary of product characteristics. In: Oncaspar. European Medicines Agency. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/oncaspar-epar-product-information_en.pdf. Accessed 10 Oct 2019."},{"issue":"7","key":"257_CR14","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","volume":"109","author":"D Douer","year":"2007","unstructured":"Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744\u201350.","journal-title":"Blood."},{"key":"257_CR15","unstructured":"Lundbeck. ELSPAR\u00ae highlights of prescribing information. In: Prescribing information. Food and Drugs Administration. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/101063s5169lbl.pdf. Accessed 10 Oct 2019."},{"key":"257_CR16","unstructured":"Jazz Pharmaceuticals. ERWINASE\u00ae summary of product characteristics. In: Summary of product characteristics. Jazz Pharmaceuticals. 2015. http:\/\/pp.jazzpharma.com\/pi\/erwinase.ie.SPC.pdf. Accessed 10 Oct 2019."},{"issue":"8","key":"257_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","volume":"15","author":"A Vora","year":"2014","unstructured":"Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15(8):809\u201318.","journal-title":"Lancet Oncol"},{"issue":"3","key":"257_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199\u2013209.","journal-title":"Lancet Oncol"},{"key":"257_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2019.07.026","volume":"120","author":"RK Jackson","year":"2019","unstructured":"Jackson RK, Liebich M, Berry P, Errington J, Liu J, Parker C, et al. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial. Eur J Cancer. 2019;120:75\u201385.","journal-title":"Eur J Cancer"},{"issue":"1","key":"257_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/leu.2016.219","volume":"31","author":"B Patel","year":"2017","unstructured":"Patel B, Kirkwood AA, Dey A, Marks DI, McMillan AK, Menne TF, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017;31(1):58\u201364.","journal-title":"Leukemia."},{"issue":"5","key":"257_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3324\/haematol.2012.073510","volume":"98","author":"WH Tong","year":"2013","unstructured":"Tong WH, van der Sluis IM, Alleman CJ, van Litsenburg RR, Kaspers GJ, Pieters R, et al. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. Haematologica. 2013;98(5):753\u20139.","journal-title":"Haematologica."},{"issue":"3","key":"257_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00043426-200203000-00004","volume":"24","author":"HA Kurre","year":"2002","unstructured":"Kurre HA, Ettinger AG, Veenstra DL, Gaynon PS, Franklin J, Sencer SF, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children\u2019s Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002;24(3):175\u201381.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"257_CR23","first-page":"388","volume":"30","author":"BG Peters","year":"1995","unstructured":"Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary. 1995;30(7):388\u201393.","journal-title":"Formulary."},{"issue":"8","key":"257_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27797","volume":"66","author":"SL Cooper","year":"2019","unstructured":"Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797.","journal-title":"Pediatr Blood Cancer"},{"key":"257_CR25","unstructured":"National Institute for Health and Clinical Excellence. Single Technology Appraisal \u2014 Pegaspargase for treating acute lymphoblastic leukaemia. In: NICE guidance. National Institute for Health and Clinical Excellence. 2016. https:\/\/www.nice.org.uk\/guidance\/ta408. Accessed 14 Oct 2019."},{"issue":"2","key":"257_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) \u2014 explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"key":"257_CR27","unstructured":"Cancer Intelligence team. Annual average number of cases of Acute Lymphoblastic Leukaemia (ICD10 C910) in the UK compiled by the Cancer Intelligence team at Cancer Research UK, upon request. In: Cancer Research UK, editor. 2011-2013 ed. Previously available at http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-all\/incidence#heading-Zero2013. Accessed 11 Oct 2019."},{"issue":"4","key":"257_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/pbc.24096","volume":"59","author":"W Furlong","year":"2012","unstructured":"Furlong W, Rae C, Feeny D, Gelber RD, Laverdiere C, Michon B, et al. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59(4):717\u201324.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"257_CR29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","volume":"54","author":"LM Vrooman","year":"2010","unstructured":"Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(2):199\u2013205.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"257_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/pbc.25757","volume":"63","author":"LM Vrooman","year":"2016","unstructured":"Vrooman LM, Kirov II, Dreyer ZE, Kelly M, Hijiya N, Brown P, et al. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63(2):228\u201333.","journal-title":"Pediatr Blood Cancer"},{"key":"257_CR31","unstructured":"National Institute for Health and Clinical Excellence. NICE clinical guideline 134, Anaphylaxis. In: NICE guidance. National Institute for Health and Clinical Excellence. 2011. https:\/\/www.nice.org.uk\/guidance\/CG134. Accessed 14 Oct 2019."},{"key":"257_CR32","unstructured":"Department of Health. NHS reference costs 2014 to 2015. In: Research and analysis. Gov.UK. 2015. https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2014-to-2015. Accessed 14 Oct 2019."},{"issue":"1","key":"257_CR33","doi-asserted-by":"publisher","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","volume":"5","author":"JJ Sacco","year":"2010","unstructured":"Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5(1):e8933.","journal-title":"PLoS One"},{"issue":"4","key":"257_CR34","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII\/ECOG E2993). Blood. 2008;111(4):1827\u201333.","journal-title":"Blood."},{"key":"257_CR35","unstructured":"The National Archives. England, National Life Tables, 1980\u201382 to 2014\u201316. In: National life tables, UK. Office for National Statistics. 1980\u201382 to 2011\u201313. https:\/\/www.ons.gov.uk\/file?uri=\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables\/current\/previous\/v2\/nltuk1315reg.xls. Accessed 2 Mar 2018."},{"issue":"2","key":"257_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","volume":"117","author":"R Pieters","year":"2011","unstructured":"Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238\u201349.","journal-title":"Cancer."},{"key":"257_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: an international perspective based on EQ-5D: Springer","author":"A Szende","year":"2014","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D: Springer; 2014."},{"issue":"8","key":"257_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1634\/theoncologist.12-8-913","volume":"12","author":"RH Mathijssen","year":"2007","unstructured":"Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist. 2007;12(8):913\u201323.","journal-title":"Oncologist."},{"issue":"9","key":"257_CR39","doi-asserted-by":"publisher","first-page":"A444","DOI":"10.1016\/j.jval.2017.08.263","volume":"20","author":"S Basu","year":"2017","unstructured":"Basu SL, PL, Saha V. The cost-effectiveness of pegaspargase for first-line treatment of acute lymphoblastic leukaemia: a cost-utility analysis. Value Health. 2017;20(9):A444.","journal-title":"Value in Health"},{"key":"257_CR40","doi-asserted-by":"crossref","unstructured":"Basu SL, PL, Rowntree C, Saha V. The cost-effectiveness of pegaspargase for first-line treatment of acute lymphoblastic leukaemia: a cost-utlilty analysis. Haematologica. 2017;102:E1465.","DOI":"10.1016\/j.jval.2017.08.263"},{"key":"257_CR41","unstructured":"Basu SL, PL, Hu X, Rowntree C, Saha V. The cost-effectiveness of pegaspargase for the first-line treatment of acute lymphoblastic leukemia: a cost-utility analysis. Pediatr Blood Cancer. 2017;64(S3):P-0046."},{"issue":"19","key":"257_CR42","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.18.01877","volume":"37","author":"BK Albertsen","year":"2019","unstructured":"Albertsen BK, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jonsson OG, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study. J Clin Oncol. 2019;37(19):1638\u201346.","journal-title":"J Clin Oncol"},{"key":"257_CR43","doi-asserted-by":"crossref","unstructured":"Lanvers-Kaminsky C, Niemann A, Eveslage M, Beck J, Kohnke T, Martin S, et al. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Leuk Lymphoma. 2019:1\u20138.","DOI":"10.1080\/10428194.2019.1658099"},{"issue":"12","key":"257_CR44","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1080\/10428194.2019.1613537","volume":"60","author":"Robin Q. H. Kloos","year":"2019","unstructured":"Kloos RQH, Pieters R, van den Bos C, van Eijkelenburg NKA, de Jonge R, van der Sluis IM. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2019:60(12):3002-3010.","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"257_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1078155219838316","volume":"26","author":"Najeebah A Bade","year":"2019","unstructured":"Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Law JY, et al. Optimizing pegylated asparaginase use: an institutional guideline for dosing, monitoring, and management. J Oncol Pharm Pract. 2019. https:\/\/doi.org\/10.1177\/1078155219838316.","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"9","key":"257_CR46","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3324\/haematol.2018.206433","volume":"104","author":"C Rizzari","year":"2019","unstructured":"Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, Ballerini A, Matteo C, Gerss J, et al. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica. 2019;104(9):1812\u201321.","journal-title":"Haematologica."},{"issue":"7","key":"257_CR47","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/10428194.2017.1397661","volume":"59","author":"JM Ribera","year":"2018","unstructured":"Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, et al. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(7):1634\u201343.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"257_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10198-009-0173-2","volume":"10","author":"B J\u00f6nsson","year":"2009","unstructured":"J\u00f6nsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357\u20139.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"257_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1524-4733.2006.00123.x","volume":"9","author":"WB Brouwer","year":"2006","unstructured":"Brouwer WB, van Exel NJ, Baltussen RM, Rutten FF. A dollar is a dollar is a dollar \u2014 or is it? Value Health. 2006;9(5):341\u20137.","journal-title":"Value Health"},{"key":"257_CR50","unstructured":"Cancer Research UK. About chemotherapy for ALL. In: Acute lymphoblastic leukaemia (ALL). Cancer Research UK. 2018. https:\/\/www.cancerresearchuk.org\/about-cancer\/acute-lymphoblastic-leukaemia-all\/treatment\/chemotherapy\/about. Accessed 11 Oct 2019."},{"issue":"1","key":"257_CR51","doi-asserted-by":"publisher","first-page":"e27458","DOI":"10.1002\/pbc.27458","volume":"66","author":"RQH Kloos","year":"2019","unstructured":"Kloos RQH, van Litsenburg RRL, Wolf S, Wismans L, Kaspers GJL, Uyl-de Groot CA, et al. A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66(1):e27458.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"257_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/10543406.2013.860157","volume":"24","author":"H Bang","year":"2014","unstructured":"Bang H, Zhao H. Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis. J Biopharm Stat. 2014;24(2):443\u201360.","journal-title":"J Biopharm Stat"},{"issue":"6","key":"257_CR53","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/clpt.2009.162","volume":"86","author":"JC Panetta","year":"2009","unstructured":"Panetta JC, Gajjar A, Hijiya N, Hak LJ, Cheng C, Liu W, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;86(6):651\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl","key":"257_CR54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/10428199309149129","volume":"10","author":"MJ Keating","year":"1993","unstructured":"Keating MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase\u2014past, present, and future. Leuk Lymphoma. 1993;10(Suppl):153\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"257_CR55","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","volume":"11","author":"BL Asselin","year":"1993","unstructured":"Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11(9):1780\u20136.","journal-title":"J Clin Oncol"},{"issue":"16","key":"257_CR56","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","volume":"16","author":"AE Place","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O\u2019Brien JE, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677\u201390.","journal-title":"Lancet Oncol"},{"issue":"7","key":"257_CR57","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","volume":"115","author":"LB Silverman","year":"2010","unstructured":"Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351\u20133.","journal-title":"Blood."}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-019-0257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13561-019-0257-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-019-0257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:09:17Z","timestamp":1609114157000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-019-0257-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1186\/s13561-019-0257-3","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable (No human subjects were involved in this cost-effectiveness analysis).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to publication of this manuscript in BMC Health Economics Review and fulfil all authorship criteria as defined by the International Committee of Medical Journal Editors ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Subham Basu, Peggy Lin and Xingdi Hu were employees of Baxalta (now a member of the Takeda group of companies) at the time of the study. Kingsley P. Wildman was a Shire (now a member of the Takeda group of companies) employee at the time of the current study, and he has also previously been an employee of Servier. Vaskar Saha has received research grant funding from Shire, and a speakers fee for I-BFM 2018. Clare Rowntree has participated in a Shire-sponsored video project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}